In a letter sent to commercial payers, the ACR’s Insurance Subcommittee is advocating for continued coverage for telemedicine, including reimbursement parity, after the end of the declared public health emergency.
Oxford University to Study Adalimumab as Potential COVID-19 Treatment
LONDON (Reuters)—Oxford University said on Wednesday it will study whether the prescription medicine, adalimumab (Humira), is an effective treatment for COVID-19 patients—the latest effort to repurpose existing drugs as potential coronavirus therapies. Adalimumab, which is sold by AbbVie, is a type of anti-inflammatory known as an anti-tumour necrosis factor (anti-TNF) drug. Recent studies have shown…
Providers & Patients Talk to Legislators about Telehealth, Workforce Shortage
On Sept. 15, rheumatology advocates met virtually with members of Congress to share personal accounts of how telehealth is making a difference during the COVID-19 pandemic and what will help stem a workforce shortage.
Best Practices for COVID-19 Regulatory Waivers, Relief Funding & Audits
When the first laboratory-confirmed COVID-19 case was reported by the Centers for Disease Control & Prevention (CDC) on Jan. 22, it was difficult to predict an ensuing global pandemic would last for more than half the year. Approximately one week after the initial CDC report, the U.S. Department of Health & Human Services (HHS) declared…
Case Report: A COVID-19 Mimic
A 67–year-old white woman with primary Raynaud’s phenomenon presented following a week of progressively worsening shortness of breath, dry cough and generalized malaise. An avid tennis player, she first noticed dyspnea while playing, but a few days later grew short of breath even at rest. She went to an urgent care center, where a computed…
The Reliability & Utility of Serological Antibody Tests in COVID-19
Serological testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies may play a critical role in the management of the worldwide health crisis. Such testing may reveal key information for epidemiology, convalescent plasma therapies and vaccine development. However, the situation is complex, and much is unknown. Although such testing may ultimately be used to…
Staying Connected with Constituents During COVID-19
Legislative staff talk about working during the pandemic and how they are connecting with constituents.
Out-of-Pocket Costs for Patients with Rheumatic Diseases Skyrocket
An estimated one in four American adults live with a rheumatic disease, and according to a new national patient survey by the ACR, the healthcare and lifestyle challenges have become worse for these patients during the COVID-19 pandemic. Key survey findings include: Patients currently seeing a rheumatologist declined 52% between 2019 and 2020; 68% of…
Guidance Coming for Anticipated COVID-19 Vaccine
What to vaccinate for and when to do so are challenges for rheumatologists and rheumatology professionals under normal circumstances. During the COVID-19 pandemic, even more questions are being raised, specifically regarding a possible vaccine for SARS-CoV-2. The ACR’s COVID-19 Practice and Advocacy Task Force is working on a guidance document to help ACR members address these pressing questions.
Jury Out on Immunomodulatory Therapy for Kids with Severe COVID-19
NEW YORK (Reuters Health)—Immunomodulatory therapy is not recommended for most children with COVID-19 who typically will have a mild to moderate course of illness, experts advise in a guidance document in the Journal of the Pediatric Infectious Diseases Society.1 For children with severe or critical COVID-19, immunomodulatory agents “may be beneficial,” but the risks and…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 27
- Next Page »